One Mind for Research and our partner organizations hold various events throughout the year to help raise awareness and funding for brain disease research. Check back often for a list of updated events.

Watch video highlights of One Mind ‘Circle of Hope’ Celebrity Gala

1 in 3 people will suffer brain illness or injury in their lifetime.
Brain diseases and injuries cost society as much as $2 TRILLION per year in the US and EU.
Brain disorders and injuries cost society more than cancer and cardiovascular disease COMBINED.
1.7 MILLION Americans have Autism.
1.7 MILLION Americans suffer a Traumatic Brain Injury every year.
Approximately 1 million Americans suffer from Parkinson’s disease.
Over 5 million Americans have Alzheimer’s Disease.
For every soldier killed in war in 2012, about 25 veterans took their own lives.
Traumatic Brain Injury (TBI) is one of the LEADING CAUSES OF DEATH AND DISABILITY in America.
By 2023, over 46 million American adults will suffer from a mental disorder.
53,000 Americans die every year due to Traumatic Brain Injury.
8 teenagers die EVERY DAY in the US from TBI.
Neurological disorders constitute 12% of total deaths globally each year.
There are 5 MILLION Americans living with TBI-related disabilities.
Mental disorders make up 35% of the cost of all non-communicable diseases worldwide.
5.3 MILLION Americans have lifelong disabilities due to Traumatic Brain Injury (TBI).
Direct and indirect cost of TBI is $76 BILLION per year in the US.
Nearly 8% of the US population suffers from POST-TRAUMATIC STRESS in their lifetime.
300,000 soldiers suffer TBI and/or PTS.
Women are about twice as likely as men to develop PTSD.
There is 1 military suicide per day in the US.
FOUR people commit suicide EVERY HOUR in the United States.
In the U.S., serious mental illness causes earnings loss of $193.2 billion annually.
90% of suicide victims have a TREATABLE MENTAL DISORDER.
Nearly 10% of people with SCHIZOPHRENIA commit suicide.
Number one sport per capita for traumatic brain injury is GIRLS SOCCER.
HALF A MILLION children under 14 go to the emergency room every year for TBI.
Funding for brain research from government and pharmaceutical companies is DECREASING EVERY YEAR.
Someone develops Alzheimer’s Disease EVERY 68 SECONDS.
Alzheimer’s Disease is the 6th LEADING CAUSE OF DEATH in US adults.
Traumatic brain injury is the leading cause of death and disability in children and young adults.
TBI patients are up to 5 times more likely to develop Alzheimer’s disease.
Medicaid and Medicare spend $130 BILLION per year on Alzheimer’s patients.
One in 10 high school athletes involved in contact sports sustain a concussion each year.
Over 400,000 Americans have Multiple Sclerosis.
An athlete who sustains a concussion is 5 times more likely to sustain a second concussion.
People with TBI are nearly twice as likely to report binge drinking.
The lowest rates of Multiple Sclerosis are in countries nearest to the EQUATOR.
20% of U.S. troops returning from combat tours show symptoms of PTSD or major depression.
DEPRESSION is the LEADING CAUSE of disease burden in the U.S.
Nearly 7% of American adults had a MAJOR DEPRESSIVE EPISODE in the past 12 months.
81.1 million people will be affected by dementia by 2040.
Over 2 MILLION Americans over the age of 18 suffer from BIPOLAR DISORDER.
About one in 10 individuals will have at least one epileptic seizure in their lifetime.
TBI victims are 50% more likely to suffer from depression.
Over 2 MILLION Americans have SCHIZOPHRENIA.
Among people with MS, physical disability contributes to a nearly 70% unemployment rate.
The annual medical cost of Schizophrenia in the US is OVER $32B.


HOMEWARD BOUND TELETHON Sunday on the Military Channel to Benefit ONE MIND & Veteran’s Charities


Homeward Bound Telethon
Alan Alda, Joe Mantegna to host live telecast on Discovery’s Military Channel on Veteran’s Day Weekend: Sunday, November 10, 7 p.m. Eastern, 4 p.m. Pacific
Music legend Connie Francis co-hosts, show features Secretary of State John Kerry, Country Music Star Trace Adkins, Bette Midler, Henry Winkler, Dr. Phil McGraw, Lou Diamond Phillips, Blake Shelton, Kevin Spacey, Jason Bateman, James Brolin, Gloria Loring, Mark Harmon and the Cast of NCIS.
Seattle, WA (July 31, 2013): One Mind has been designated as one of the five beneficiaries of the 1st Annual Homeward Bound Telethon, which will be broadcast on the Military Channel this Sunday, November 10 at 7 p.m. Eastern and 4 p.m. Pacific.
Alan Alda and Joe Mantegna will host the four-hour national telethon to support American veterans suffering from Post-Traumatic Stress (PTS) and Traumatic Brain Injury (TBI). Presented by Haven from the Storm the telethon will be broadcast live from the historic American Legion Hall #43 in Hollywood.
Haven From the Storm founder Leonard Wilf commented, "It's important to recognize the valiant contributions made by brave American soldiers, veterans who protect our country, and return home with PTS and TBI. This cause is in my heart and I suspect that's true for many Americans who care."
Participating charities include: One Mind for Research, American Red Cross; New York Presbyterian Hospital; Operation Finally Home, and the Wounded Warrior Project. PEOPLE magazine has teamed up with HOMEWARD BOUND because of it’s commitment to the men and women who served in the military.  A portion of the night’s proceeds will go to one of PEOPLE’s charities, Operation Finally Home, which has built more than 30 custom-designed mortgage free homes for wounded and disabled veterans. 
The first two hours of the telethon will also air on Tribune’s PIX11 (New York) from 7 – 9:00 PM ET; WGN (Chicago) from 10:30 PM – 12:30 AM (delayed)(CT); and on KTLA (Los Angeles) from 4 – 6:00 PM (PT). The telethon will be live-streamed on and rebroadcast on the Armed Forces Network on Monday, November 11, 2013. Donations to support the telethon can also be made at
About ONE MIND for Research™
ONE MIND is an independent 501(c)(3) non-profit organization dedicated to curing the diseases of the brain and eliminating the stigma and discrimination associated with mental illness and brain injuries. ONE MIND sponsors groundbreaking new research, creates public-private partnerships, and is building a brain data exchange portal for shared scientific data. Our mission is to accelerate the development of improved diagnostics, more effective treatments, and, ultimately, preventions and cures for all types of mental illness and brain injury. ONE MIND works to find real solutions to the epidemic of brain disease, improving the lives of current and future generations. More information can be found at
For more information, contact:
Lenny O’Donnell
Chief Marketing & Communications Officer
206.457.8403 x103


New Approaches and Incentives in Drug Development



When: November 22, 2013

Time: 9:00 am – 3:15 pm

Where: National Academy of Sciences Building, Room NAS120
2101 Constitution Avenue, NW
Washington, DC 20418


If you would like to request an invitation to this conference, please e-mail your name, company, and title to: Thank you.


Escalating drug development costs, and a dearth of high-impact innovation, are highly visible problems for the biopharmaceutical industry. Recent legal developments, most notably the U.S. Supreme Court’s June 2013 decision in Federal Trade Commission (FTC) v. Actavis, further alter the incentive landscape. Actavis suggests decreased judicial tolerance for patent litigation settlements in which brand-name drug manufacturers pay generic firms arguing patent invalidity or non-infringement to drop the lawsuit. One possible consequence is a decrease in effective patent term for small molecule drugs.


As the incentive landscape is changing, new R&D strategies are also emerging. For example, efforts are underway to find, and validate clinically, entirely new uses for existing molecules – either molecules that have been abandoned in clinical trials for lack of efficacy or generic molecules. Firms, government funders, and patient groups are also involved in a variety of different precompetitive research collaborations.


Both existing and new innovation models raise the question of how well the current incentive system works for biopharmaceutical development, particularly in the context of small molecules. Should additional or alternative economic incentives, such as targeted public funding or exclusivity terms based on research risk or disease, be considered?


The center’s inaugural conference brings together leading figures from the private sector, government, and academia to address these questions. Morning sessions will discuss the existing incentive regime and the impact of FTC v. Actavis. They will also address how new research models, such as drug “rescue and repurposing” and precompetitive collaborations to validate drug targets, could best invoke the existing array of incentives. The afternoon session will discuss how innovation incentives in drug development already differ substantially from innovation incentives in other industries. It will also discuss whether additional or alternative incentives are needed.


Agenda (tentative)


Panel 1: 9:00 am -10:00 am

The Current Incentive Landscape


Moderator: Stuart Benjamin, Duke Law School


Michael Carrier, Rutgers Law School

Bhaven Sampat, Columbia School of Public Health

Bret Dickey, Executive Vice President, Compass Lexecon

Arti Rai, Duke Law School


Panel 2: 10:00 am - 12:00 pm

Working within the Current Regime: Rescue, Repurposing, and Precompetitive Collaborations


Moderator: Arti Rai, Duke Law School


Christine Colvis, National Center for Advancing Translational Sciences, NIH

Charles Niebylski, National Center for Advancing Translational Sciences, NIH

Dominique Pahud, Director in Innovation and Networks, Ewing Marion Kauffman Foundation

Craig Wegner, Executive Director, Translational Sciences, AstraZeneca

Aled Edwards, University of Toronto, Structural Genomics Consortium

Lon Cardon, Senior Vice President for Alternative Discovery and Development, Glaxo Smith Kline

Bernard Munos, Founder, Innothink Center for Research in Biomedical Innovation


LUNCH (12:15 pm - 1:15 pm): Luncheon keynote: Chris Austin, Director of NIH’s National Center for Advancing Translational Sciences (NCATS)


Panel 3: 1:15 pm – 1:45 pm

A Comparison of Drug Development with Innovation in Other Industries


Moderator: Stephen Johnson, Chief Intellectual Property and Policy Officer, One Mind for Research


Philip Johnson, Senior Vice President and Chief Intellectual Property Counsel, Johnson & Johnson

Gail Levine, Vice President and Associate General Counsel, Intellectual Property, Verizon Communications, Inc.


Panel 3, continued: 1:45pm -3:15 pm

Alternative or Additional Incentives for Drug Development


David Ridley, Duke Fuqua School of Business

Aaron Kesselheim, Harvard School of Public Health

Ben Roin, Harvard Law School

Brian Caveney, Vice President and Medical Director of Healthcare Consulting, Blue Cross and Blue Shield of North Carolina

Amy Comstock Rick, Chief Executive Officer, Parkinson’s Action Network


Commentator: Jerome Reichman, Duke Law School




Conference Organizers


Stuart M. Benjamin

Douglas B. Maggs Professor of Law

Associate Dean for Research


Arti K. Rai

Elvin R. Latty Professor of Law


with thanks to Stephen Johnson

of One Mind for Research




Conference Sponsors




For more information, contact:


Balfour Smith

Program Coordinator

Center for Innovation Policy

Duke University School of Law

210 Science Drive / Box 90360

Durham, NC 27708-0360






Past Events Archive